Checkpoint blockade immunotherapy (CBI), such as anti-CTLA-4 and anti-PD-1/PD-L1, works to reactivate the CD8 T cells and can lead to better patient outcomes in multiple cancer types (Christofi et al., 2019). This evidence concerns the gene CTLA4 and cancer.